New York, US-based Actinium Pharmaceuticals has appointed Gregory Bergonio as director of clinical operations, with particular responsibility for its Actimab-A phase II clinical trial programme.
Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm’s oncology global development unit, specialising in acute myeloid leukaemia.
Prior to this, Bergonio held a number of clinical research management positions at Bausch & Lomb, OSI Eyetech, Forest Laboratories, i3 Research and Kern McNeil.
Sandesh Seth, Actinium’s executive chairman, said: “We are very excited to welcome Greg to the clinical development team at Actinium.
“Greg’s joining comes at an ideal time given our increased development efforts as a result of the Actimab-A phase II trial and Iomab-B pivotal phase III SIERRA trial.
“Greg’s direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our current and planned clinical development efforts.”